The New England Journal of Medicine

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been ...
Healio

Immunotherapy improves beta-cell function, delays type 1 diabetes diagnosis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single 14-day course of the monoclonal antibody ...
The New England Journal of Medicine

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte–mediated ...
Yahoo Finance

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide ...

REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of ...
Healio

Once-daily JAK inhibitor helps preserve beta-cell function in type 1 diabetes

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Children and adults with type 1 diabetes receiving ...

Beta-blockers are no longer needed in post-infarction patients with normal heart function, study confirms

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international ...
Morningstar

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...